Teplizumab for new-onset T1D (Tzield)

The approach: protect what's left, after diagnosis

By the time someone is diagnosed with clinical (stage 3) type 1 diabetes, the immune system has already destroyed most insulin-producing cells — but usually not all of them. There is a "honeymoon" window in which the pancreas still makes some of the body's own insulin, and that residual function makes glucose easier to manage and lowers the risk of complications.¹ Teplizumab tries to defend that remaining capacity by interrupting the attack.

Teplizumab is an Fc-receptor-nonbinding anti-CD3 monoclonal antibody. It binds the CD3 receptor on T cells, blunting the autoreactive T cells that destroy insulin-producing cells and shifting the immune balance toward less-destructive, "exhausted" and regulatory T-cell populations.¹ Importantly, it is a short, defined course of immune modulation — not the continuous, lifelong immunosuppression used for transplants.²

This is the same drug already FDA-approved as Tzield to delay the onset of stage 3 disease in stage-2 (presymptomatic) people, which is covered under Preventing. This entry is the distinct new-onset / stage-3 use: giving it after diagnosis to preserve the cells a person still has.³

Clinical evidence

The idea is not new. A 2002 randomized trial first showed a single 14-day anti-CD3 course given within 6 weeks of diagnosis maintained or improved insulin production at one year in most treated patients,⁴ and follow-up showed the benefit persisted for at least two years without ongoing immunosuppression.⁵ A later open-label trial (AbATE) found two courses slowed C-peptide decline by about 75% at two years, while highlighting that only a subgroup were strong responders.⁶ An earlier phase-3 program (Protégé) missed its composite endpoint of low insulin use plus near-normal HbA1c at one year, a sobering reminder that C-peptide gains don't automatically translate into easier glucose control.⁷

The pivotal modern evidence is the phase-3 PROTECT trial (NCT03875729): 328 children and adolescents aged 8–17, diagnosed within 6 weeks and with C-peptide still detectable, received two 12-day intravenous teplizumab courses (six months apart) or placebo, 2:1.¹ At 78 weeks, treated patients had significantly higher stimulated C-peptide (least-squares mean difference 0.13 pmol/mL; 95% CI 0.09–0.17; P<0.001), and 94.9% kept a clinically meaningful C-peptide level (≥0.2 pmol/mL) versus 79.2% on placebo.¹ Crucially, the secondary endpoints that patients feel day to day — insulin dose, HbA1c, time in range, and hypoglycemia — did not differ between groups.¹ No continuous immunosuppression is required; the treatment is the two defined infusion courses.¹

Durability, eligibility and safety

Durability is the honest weak point: the effect is a slowed decline measured over roughly two years from two courses, and insulin-making capacity still falls — there is no established re-dosing schedule to extend it.¹⁶ Eligibility for the approved new-onset use is narrow: stage 3, ages 8–17, treated within weeks of diagnosis while C-peptide is still present.⁸ Common side effects are transient lymphopenia, rash, headache, gastrointestinal symptoms, and mild cytokine-release symptoms, mostly clustered around the infusions and generally self-limited.¹

Maturity and availability

In June 2026 the FDA granted accelerated approval for teplizumab to delay the decline in the body's own insulin production in children aged 8–17 recently diagnosed with stage 3 T1D — the first disease-modifying therapy approved for the newly-diagnosed population.⁸ Because approval rests on C-peptide as a surrogate endpoint, it came through the Accelerated Approval pathway, and a confirmatory phase-3 trial, BETA-PRESERVE (NCT07088068), is enrolling.⁸⁹ For now availability is US-only and the drug is IV-delivered.⁸

What's coming

The near-term question is confirmation: BETA-PRESERVE must show the C-peptide benefit translates into outcomes that matter, or the accelerated approval could be revisited.⁸ Beyond that, the field increasingly views teplizumab as a foundation rather than a finished answer — a way to quiet the attack that could be paired with cell-replacement or regeneration therapies to protect new insulin-producing cells, and a candidate for earlier, broader, or repeated dosing to push a "preserve" effect closer to a lasting one.¹

References

1. Ramos EL, et al. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes (PROTECT). N Engl J Med (2023). According to PubMed (PMID 37861217); DOI. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

2. Herold KC, et al. A single course of anti-CD3 monoclonal antibody results in improvement in C-peptide responses for at least 2 years after onset of type 1 diabetes. Diabetes (2005). According to PubMed (PMID 15919798); DOI. ↩

3. U.S. Food and Drug Administration. FDA Approves Drug for Pediatric Stage 3 Type I Diabetes (content current June 12, 2026). https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes ↩

4. Herold KC, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002). According to PubMed (PMID 12037148); DOI. ↩

5. Herold KC, et al. A single course of anti-CD3 monoclonal antibody results in improvement in C-peptide responses for at least 2 years after onset of type 1 diabetes. Diabetes (2005). According to PubMed (PMID 15919798); DOI. ↩

6. Herold KC, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes (AbATE): metabolic and immunologic features identify a subgroup of responders. Diabetes (2013). According to PubMed (PMID 23835333); DOI. ↩ ↩²

7. Sherry N, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011). According to PubMed (PMID 21719095); DOI. ↩

8. U.S. Food and Drug Administration. FDA Approves Drug for Pediatric Stage 3 Type I Diabetes (content current June 12, 2026). https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes ↩ ↩² ↩³ ↩⁴ ↩⁵

9. National Library of Medicine. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (BETA-PRESERVE). ClinicalTrials.gov NCT07088068; last update posted June 8, 2026. https://clinicaltrials.gov/study/NCT07088068 ↩